Press
October 29, 2024
Nvidia-backed AI firm Iambic unveils drug discovery ‘breakthrough’
Related articles
Iambic Announces Pricing of Initial Public Offering
Publication
October 14, 2026
Iambic Announces Pricing of Initial Public Offering
Read more
Publication
October 5, 2026
Iambic Submits IND for a Potentially Brain-Penetrant KIF18A Inhibitor IAM217, Its Second Wholly Owned AI-Discovered Candidate
Read more
Publication
September 21, 2026
Iambic Launches Enchant v3 – Molecular Superintelligence Designed to Advance End-to-End Drug Discovery & Development
Read more
View more
Let's work together
Leverage the Iambic discovery process for your program. Reach out to us at partnerships@iambic.ai.
Contact us
Better technology for better medicines
GET IN TOUCH
contact@iambic.ai
(619) 330-5499
COMPANY
AboutNews & MediaCareersContactInvestors
TECHNOLOGY
PlatformPipelinePartners
Privacy Policy
Terms of Use
Copyright © 2026 Iambic Therapeutics, Inc. All Rights Reserved.